Mykor raises £4m from Clean Growth Fund and The FSE Group to scale production of fungal insulation panels.
The Bristol biotech secured the backing to expand manufacturing capabilities and grow its footprint across European markets.
Mykor is a Bristol-based biotech firm that grows fungal mycelium materials to produce structural insulation panels for the construction industry.
Mykor has secured £4m in a funding round co-led by Clean Growth Fund and The FSE Group, alongside participation from returning investor Green Angel Ventures and grant support from Innovate UK. The capital will support the company as it scales manufacturing operations and expands into further European markets.
The Bristol-based biotech firm produces MykoSIP, a prefabricated structural insulated panel grown from mycelium and agricultural waste. The product aims to address the construction sector's heavy carbon footprint by offering lower embodied carbon emissions and fire safety ratings that meet mainstream regulatory standards.
The fresh capital follows a £2m seed round and brings Mykor's total funding to £7.5m. The company has already established commercial agreements with developers across the UK and Europe as it prepares for full commercial production and the launch of a new production facility in Belgium.
From the founder
"Decarbonising construction cannot come at the expense of cost or performance. The challenge has been scaling biomaterials industrially and integrating them into real construction supply chains."
Olivia Page
Founder at Mykor
Investor perspective
"Mykor addresses one of construction’s biggest challenges: reducing embodied carbon without adding cost or complexity. Their solution integrates into existing building practices while delivering meaningful carbon savings."
Susannah McClintock
Investment Partner, Clean Growth Fund
Use of funds
- 01Expand into international markets
- 02Build out infrastructure
